FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>CAVANAUGH JAMES H</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol LEAP THERAPEUTICS, INC. [ LPTX ]							Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner					
	AP THERA	PEUTICS, INC.	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/23/2017							Officer (give title below)  Other (specify below)					
47 THORNDIKE STREET SUITE B1-1  (Street)  CAMBRIDGE MA 02141				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person						
(City)	(S	itate)	(Zip)														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transa Date (Month/D			е	action 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 5)				Benefici Owned I	es ally Following	Form:	Direct I Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership			
						Code	v	Amount	mount (A) or (D)			nsaction(s) str. 3 and 4)			Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	4. Transa Code 8)		of		6. Date Exercisab Expiration Date (Month/Day/Year)		of Securities		ies g Derivativ	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount of Number of Shares					
Stock Option (Right to Buy)	\$9.9	01/23/2017		A		11,000		(1)	01/	/22/2027	Common Stock, \$0.001 par value per share	11,000 <sup>(1</sup>	\$0	11,00	00	D	
Stock Option (Right to Buy)	\$9.9	01/23/2017		A		15,000		(2)	01/	/22/2027	Common Stock, \$0.001 par value per share	15,000 <sup>(2</sup>	\$0	15,00	00	D	

## Explanation of Responses:

- 1. The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan and is fully vested as of the grant date.
- 2. The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 12 equal quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 23, 2017, the Vesting Start Date.

/s/ Douglas E. Onsi as attorneyin-fact for James Cavanaugh 01/23/2017

\*\* Signature of Reporting Person Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$ 

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.